TROP2-directed ADC

A TROP2-directed antibody-drug conjugate (ADC) is a class of targeted cancer therapeutics designed to selectively deliver cytotoxic payloads to tumor cells expressing trophoblast cell surface antigen 2 (TROP2). TROP2 is a transmembrane glycoprotein overexpressed in various epithelial tumors, including breast, lung, urothelial, and gynecological cancers, while showing limited expression in normal tissues. These ADCs typically consist of a humanized anti-TROP2 monoclonal antibody covalently linked to a potent cytotoxic agent (such as a topoisomerase I inhibitor or microtubule inhibitor) via a cleavable or non-cleavable linker. Upon binding to TROP2 on the cancer cell surface, the ADC is internalized, and the payload is released to induce cell death, often accompanied by a bystander effect that kills neighboring tumor cells.

Other names

TROP-2 ADCTROP2 ADCTROP 2 ADCTROP2-directed antibody-drug conjugateTROP-2-directed antibody-drug conjugateTROP 2-directed antibody-drug conjugate